Development and validation of the UV spectroscopic method for varenicline determination in pharmaceutical preparation
Keywords:
UV visible spectroscopic method, varenicline, smockingAbstract
A simple and accurate UV visible spectroscopic method has been developed and validated for quantification of varenicline in bulk drug and pharmaceutical dosage forms. A shimadzu UV spectrophotometer was used considering availability and cost effectiveness of the proposed method. λmax of 236nm and 319nm were observed from the spectroscopic method. The calibration curve was linear (r = 0.99) in the studied range of concentration (5- 40 µg /ml) in both the absorption maxima. The selectivity and sensitivity of the elaborated method were satisfactory, and the limits of detection and quantification were less than 20% of the specification level. Moreover, the inter- and intra-day precisions was found to be less than 3% (RSD), while the recovery values expressing inter- and intra-day accuracy was varied from 99.73 to 101.23. The varenicline solution was stable over a period of 3 days on storage under refrigeration. The utility of the developed method was examined by analyzing the tablets containing VAR. As a result, the method was found to be selective, sensitive, precise and accurate.
Downloads
References
Carpenter, M. J., Jardin, B. F., Burris, J. L., Mathew, A. R., Schnoll, R. A., Rigotti, N. A., & Cummings, K. M. J.D. (2013). Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. 73(5), 407-426.
Development and validation of the HPLC method for varenicline determination in pharmaceutical preparation. 30(3), 142-146.
Hajek, P., Smith, K. M., Dhanji, A.-R., & McRobbie, H. J. B. m. (2013). Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. 11(1), 1-7.
Jiloha, R. J. I. j. o. p. (2010). Biological basis of tobacco addiction: Implications for smoking-cessation treatment. 52(4), 301.
Kadi, A. A., Mohamed, M. S., Kassem, M. G., & Darwish, I. A. J. C. C. J. (2011). A validated stability- indicating HPLC method for determination of varenicline in its bulk and tablets. 5(1), 1-6.
Koegelenberg, C. F., Noor, F., Bateman, E. D., van Zyl-Smit, R. N., Bruning, A., O’Brien, J. A., . . . Esterhuizen,
Kwak, S. S., Lee, E. S., Yoon, H. Y., Kim, C. H., Goo, Y. T., Kang, M. J., . . . Therapy. (2018). Immediate release tablet formulation of varenicline salicylate and comparative pharmacokinetic study in human volunteers. 12, 3377.
Pietras, R., Szymanska, K., Kondej, M., Gladysz, A., Kowalczuk, D. J. C. I. i. P., & Sciences, M. (2017).
Pujeri, S. S., Khader, A., & Seetharamappa, J. J. S. P. (2012). Stress degradation studies on varenicline tartrate and development of a validated stability-indicating HPLC method. 80(1), 115-126.
Silagy, C., Lancaster, T., Stead, L. F., Mant, D., & Fowler, G. J. C. d. o. s. r. (2004). Nicotine replacement therapy for smoking cessation. (3).
T. M. J. J. (2014). Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. 312(2), 155-161.
Wilkes, S. J. I. j. o. c. o. p. d. (2008). The use of bupropion SR in cigarette smoking cessation. 3(1), 45.
Young, K. M., & Davis, J. M. J. C. c. r. (2019). Combination of varenicline and nicotine patch for smoking cessation: A case report. 7(9), 1670-1672.
Zatonski, W., Cedzynska, M., Tutka, P., & West, R. J. T. C. (2006). An uncontrolled trial of cytisine (Tabex) for smoking cessation. 15(6), 481-484.
Zierler-Brown, S. L., & Kyle, J. A. J. A. o. P. (2007). Oral varenicline for smoking cessation. 41(1), 95-99.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
